undamentalytics Newsletter
Sign in

Scynexis Inc income statement

In fiscal 2025, Scynexis Inc reported revenue of $20.6m, up 449.9% on the year before, operating income of −$16.1m (a -78.0% margin) and net income of −$8.6m, or −$0.17 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2013Dec 20132014Dec 20142015Dec 20152016Dec 20162017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Revenue171200000013514042119
Cost of revenue1615————————————
Gross profit14————————————
Research and development48162018223837242731262226
Selling, general and administrative48128891115506321141416
Operating income−7−15−28−28−26−30−49−51−61−8673−37−16−23
Interest expense—0−001211353100
Income before tax—−7−28−30−25−19−54−58−36−6867−21−9—
Income tax0−1000−70−3−3−5000—
Net income−47−6−33−30−25−12−54−55−33−6367−21−9−10
Diluted EPS−$34.87−$6.72−$1.34−$7.90————−$1.25−$1.47$1.39−$0.44−$0.17—
Diluted shares (average)—2m2m4m5m9m11m11m26m43m48m49m50m—
EBITDA−6−13−28−28−26−30−49−51−60−8573−37——

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: CELU vs SCYXCTMX vs SCYXPRQR vs SCYX

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Scynexis Inc's SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Scynexis Inc.